Use of Swedish 'snus' is linked to a doubled risk of pancreatic cancer

Tobacco smoking is a known risk factor for pancreatic cancer, which is an unusually malignant form of the disease. Since it is common for people who take snus – a tobacco product designed for insertion between the gum and upper lip – to also smoke cigarettes, the challenge facing epidemiological research into snus and cancer has been to isolate the effects of the different kinds of tobacco. What makes this new study unique is that it has been possible to study the correlation between snus and cancer risk in a large enough group of men who have never smoked.

The subjects attended health check ups between 1978 and 1992, during which they were asked to report on their smoking and 'snusing' habits. The researchers have also studied rates of oral and lung cancer amongst the men, but found no correlation to snus.

“We're actually not that surprised,” says project leader Professor Olof Nyrén of the Department of Medical Epidemiology and Biostatistics. “Pancreatic cancer has been under discussion in several earlier epidemiological studies on humans, both regarding Scandinavian snus and American smoke-free tobacco. On the other hand, previous studies of oral and lung cancer in relation to Scandinavian snus have been negative.”

The main contribution of the new study is its conclusion that Swedish moist snus can be carcinogenic. However, the study also shows that the risks for users are small, and, as far as can be judged, much smaller than the risks associated with smoking.

“If 10,000 non-smoking snus users are monitored for ten years, according to our data, eight or nine of them will develop pancreatic cancer, as opposed to four amongst those who use neither product. But 9,991 won't, so the odds aren't that bad,” he says.

The debate on whether the net effect of snus is positive or negative has been raging for many years. Some scientists and health carers have advocated the use of snus, as it is likely to lead to that people will smoke less. However, Professor Nyrén argues that it is important to have all the facts on the table before any advice can be given about snus as a way to cut down on smoking.

“We don't only need reliable and accurate measures of the risks of both smoking and taking snus, we also need know the effects of other, alternative methods to cut smoking. We also have to be certain that an increase in snus marketing will not cause addictions in young people who otherwise wouldn't have started to smoke,” he says.

Publication:
“Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung and pancreas in male construction workers; a retrospective cohort study”
Juhua Luo, Weimin Ye, Kazem Zendehdel, Johanna Adami, Hans-Olov Adami, Paolo Boffetto, Olof Nyrén

The Lancet, online, 10 May 2007

For further information, please contact: Professor Olof Nyrén Tel: +46 (0)8-524 861 95 or +46 (0)70-7428020 (mobile) Email: olof.nyrén@ki.se Press Officer Katarina Sternudd Tel: +46 (0)8-524 838 95 or +46 (0)70-224 38 95 (mobile) Email: katarina.sternudd@ki.se Karolinska Institutet is one of the leading medical universities in Europe. Through research, education and information, Karolinska Institutet contributes to improving human health. Each year, the Nobel Assembly at Karolinska Institutet awards the Nobel Prize in Physiology or Medicine.